licensing agreement

Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.

The technology uses Thermo Fisher Scientific microarrays to measure transcript levels in order to diagnose rejection of solid organ transplants.

The contract includes a milestone of approval by the Chinese Food and Drug Agency within the next three years.

MDxHealth will use Ghent's methylation in situ hybridization technology to develop tests for urological cancers.

The firm said that the technologies it has licensed improve PCR and RT-PCR amplification of DNA and RNA.

Laboratoire Cerba was granted the right to develop a tumor expression test based on IntegraGen's proprietary microRNA biomarker.

MBL will use the technology primarily for its diagnostic reagents business. 

The technologies monitor patient response to immunotherapies. 

Both companies plan to offer the test to researchers and clinicians to help better determine when a patient can be diagnosed with an infectious disease.